Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

149.22
+6.284.39%
Post-market: 151.001.78+1.19%19:58 EDT
Volume:18.77M
Turnover:2.80B
Market Cap:19.78B
PE:-43.82
High:151.85
Open:145.61
Low:144.27
Close:142.94
52wk High:151.85
52wk Low:40.36
Shares:132.57M
Float Shares:127.00M
Volume Ratio:7.12
T/O Rate:14.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4049
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-17.15%
PB:-109.25
PE(LYR):-44.94

Loading ...

Movement Alert|Guardant Health Rises 5.08% in Regular Trading, Multiple Catalysts Continue to Drive Momentum

Market Focus
·
Yesterday

Guardant Health Price Target Announced at $175.00/share by Bernstein

Dow Jones
·
Jun 26

GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM

TIPRANKS
·
Jun 26

U.S. Research Roundup-american Tower, H.B. Fuller Company, TD Synnex

Reuters
·
Jun 26

Movement Alert|Guardant Health Rises 5.05% in Regular Trading, Multiple Catalysts Drive Continued Rally

Market Focus
·
Jun 25

Guardant Health is Maintained at Overweight by Barclays

Dow Jones
·
Jun 24

Guardant Health price target raised to $150 from $120 at Barclays

TIPRANKS
·
Jun 24

Guardant Health director Myrtle S. Potter disposes of 1,556 common shares worth $204,084.96

Reuters
·
Jun 24

Hikma joins Guardant Health as platinum sponsor at UAE International Oncology Forum IOF 2026

Reuters
·
Jun 22

Guardant Health shareholders elect directors at annual meeting

Reuters
·
Jun 19

Living Longer Is Big Business. These Stocks Will Benefit. -- Barrons.com

Dow Jones
·
Jun 19

What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders

Simply Wall St.
·
Jun 18

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health (GH)

TIPRANKS
·
Jun 17

U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower

Reuters
·
Jun 17

Guardant Health Inc : Jefferies Raises Target Price to $150 From $130

THOMSON REUTERS
·
Jun 17

Guardant Health director Tariq Musa disposes of 116 common shares for $15,102.04

Reuters
·
Jun 17

Guardant Health CIO Kumud Kalia sells 3,418 shares worth $445,156.57

Reuters
·
Jun 16

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

GlobeNewswire
·
Jun 15

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

GlobeNewswire
·
Jun 15

Guardant Health CIO Kumud Kalia sells 5,000 common shares worth $652,030.00

Reuters
·
Jun 13